Autolus Therapeutics plc - ADR

NASDAQ:AUTL  
6.17
-0.03 (-0.48%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)444.50M
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$0.29 Million
Adjusted EPS-$0.51
See more estimates
10-Day MA$6.15
50-Day MA$6.40
200-Day MA$6.62
See more pivots

Autolus Therapeutics plc - ADR Stock, NASDAQ:AUTL

The Mediaworks, 191 Wood Lane, London, Greater London W12 7FP
United Kingdom
Phone: +44.20.3829.6230
Number of Employees: 384

Description

Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells. The company was founded by Martin Pule in September 2014 and is headquartered in London, the United Kingdom.